Life sciences investor Portal Innovations eyes $100M seed fundnews2025-08-12T11:00:57+00:00August 12th, 2025|Endpoints News|
Bayer licenses early-stage KRAS cancer drug from Kumquat for up to $1.3Bnews2025-08-12T10:57:42+00:00August 12th, 2025|Endpoints News|
BridgeBio’s oncology spinout sticks with SPAC to land on Nasdaqnews2025-08-11T20:30:11+00:00August 11th, 2025|Endpoints News|
Vaxart receives second stop-work order for next-gen Covid vaccine news2025-08-11T20:13:56+00:00August 11th, 2025|Endpoints News|
What does Prasad’s surprise return to CBER mean for the FDA?news2025-08-11T17:25:29+00:00August 11th, 2025|Endpoints News|
NextRNA, a long non-coding RNA startup working with Bayer, to wind downnews2025-08-11T15:40:55+00:00August 11th, 2025|Endpoints News|
IO Biotech to seek FDA filing even though cancer vaccine narrowly fails pivotal skin cancer studynews2025-08-11T15:33:45+00:00August 11th, 2025|Endpoints News|
Sitryx gets back rights to drug from Lilly deal; Humacyte is cutting costsnews2025-08-11T14:05:56+00:00August 11th, 2025|Endpoints News|
Novartis’ antibody drug ianalumab passes two Phase 3 studies in Sjögren’s diseasenews2025-08-11T10:50:04+00:00August 11th, 2025|Endpoints News|
